Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.
Press releases published on July 9, 2025
FDA Clears Updated Magstim Rapid Transcranial Magnetic Stimulation Research System
GlobeNewswire
·
July 9, 2025
MINNEAPOLIS, July 09, 2025 (GLOBE NEWSWIRE) -- The FDA has cleared the new Magstim Rapid TMS system for research and clinical applications, now with FDA clearance in the U.S. for the treatment of pain*. Cited in thousands of peer-reviewed studies and …
Enteral Feeding Devices Market worth US$3,994.2 million by 2030 with 6.0% CAGR | MarketsandMarkets™.
GlobeNewswire
·
July 9, 2025
Delray Beach, FL, July 09, 2025 (GLOBE NEWSWIRE) -- The global enteral feeding devices market, valued at US$2,807.9 million in 2024, stood at US$2,965.1 million in 2025 and is projected to advance at a resilient CAGR of 6.0% from 2025 to 2030, culminating …
INVO Fertility Enhances INVOcell Technology with Expanded Awareness, Training, and Improved Pricing
GlobeNewswire
·
July 9, 2025
SARASOTA, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, today announced further efforts to drive its comprehensive strategy to enhance …
Dandy Launches America’s First Two-Visit Dentures for Medicaid, Medicare, and Low-Paying PPOs
GlobeNewswire
·
July 9, 2025
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Dandy, America’s fully digital dental lab, today announced the first premium denture solution priced for government health plans*. With its two-appointment workflow and turnaround in less than 10 days, Dandy’s …
Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration
GlobeNewswire
·
July 9, 2025
Joint research program targets new treatments for life-threatening complication of brain hemorrhage An international discovery collaboration is harnessing AI-powered drug discovery to develop a first-in-class therapy to prevent delayed cerebral ischemia in …
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
GlobeNewswire
·
July 9, 2025
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts trial profile Enrollment in Part A of MIRACLE reaches …
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
GlobeNewswire
·
July 9, 2025
GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
TRIMEDX ranked 30th Inspiring Workplace in North America and recognized as Best in Class Leadership
GlobeNewswire
·
July 9, 2025
Indianapolis, Indiana, July 09, 2025 (GLOBE NEWSWIRE) -- TRIMEDX―a leading independent clinical asset management company delivering clinical engineering services, clinical asset informatics, and medical device cybersecurity― is proud to announce it has …
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
GlobeNewswire
·
July 9, 2025
LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) to evaluate …
Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements
GlobeNewswire
·
July 9, 2025
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today …
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire
·
July 9, 2025
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for …
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
GlobeNewswire
·
July 9, 2025
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- …
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
GlobeNewswire
·
July 9, 2025
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Vireo Growth Inc. Announces Retirement of November 2024 Convertible Note
GlobeNewswire
·
July 9, 2025
-- Company concurrently refinances convertible note on amended terms in conjunction with larger refinancing -- MINNEAPOLIS, July 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF) today announced the …
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
GlobeNewswire
·
July 9, 2025
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today …
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 9, 2025
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell …
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
GlobeNewswire
·
July 9, 2025
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a …
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
GlobeNewswire
·
July 9, 2025
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
GlobeNewswire
·
July 9, 2025
PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
GlobeNewswire
·
July 9, 2025
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 ( …